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ABSTRACT  
Objectives: Cromolyn, a potent and safe anti-inflammatory drug, is used as a safe medication for the prophylactic treatment of asthma. The present 
study explores its anti-inflammatory and anti-angiogenic potential of cromolyn by analysing the expression pattern of inflammatory (NF-κB, COX-2, 
iNOS, IL-6 and IL-10) and angiogenic (VEGF) in 7, 12-dimethylbenz(a)anthracene (DMBA) induced hamster buccal pouch carcinogenesis.  
Methods: Topical application of 0.5% DMBA (three times a week) in the buccal pouches of hamsters resulted in well differentiated squamous cell 
carcinoma after 14 w.  
Results: While tumor formation was observed in all the hamsters treated with DMBA alone, we noticed only precancerous lesions such as 
hyperkeratosis, hyperplasia, and mild dysplasia in DMBA+cromolyn treated hamsters. Furthermore, cromolyn prevented the dysregulation induced 
by DMBA on the expression pattern of inflammatory and angiogenic markers.  
Conclusion: The present study thus concludes that the tumor preventive potential of cromolyn relies on its anti-inflammatory and anti-angiogenic 
potential in 7, 12-dimethylbenz(a)anthracene induced hamster buccal pouch carcinogenesis. 
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INTRODUCTION 
Oral carcinoma is one of the most predominant health problems 
worldwide, and it is the leading cause of cancer-related deaths in the 
developing countries including India. This disfiguring malignant 
cancer affects the overall life quality of the patients and imposes a 
significant burden to their families. Though oral cancer is an avoidable 
one, lack of awareness of oral cancer symptoms, late diagnosis and 
sometimes clinician’s carelessness or mis prescription are responsible 
for the increased annual incidence of oral cancer. Since tobacco and 
alcohol abuse are documented as the major risk factors of oral cancer, 
avoiding or quitting, such habits may enormously decrease the 
incidence of oral cancer. Also, early diagnosis and treatment 
modalities at an early stage could definitely improve the life quality of 
the patients as well as overall 5 y survival outcomes [1, 2]. 
Golden Syrian hamsters are the preferred experimental model to 
study the biochemical, molecular or morphological aspects of oral 
carcinogenesis. This is due to the fact that hamsters possess a pocket 
like an anatomy in their mouth known as “buccal pouches”, which can 
retain the topical application of carcinogens for a longer time [3]. 7,12-
dimethylbenz(a)anthracene, the procarcinogen, elicits its tumorigenic 
behavior through its active metabolite, dihydro diol epoxide, upon 
metabolic activation in the host. Chronic inflammation, excessive 
generation of reactive oxygen species and extensive DNA damage are 
also documented as a responsible phenomenon for DMBA mediated 
oral carcinogenesis in experimental animals [4, 5]. 
Cromolyn is one of the most promising drugs used in the treatment of 
asthma. Cromolyn has been regarded as a potent anti-inflammatory 
agent and thus used for mast cell stabilization [6]. Extensive studies 
reported its anti-inflammatory, antidiabetic and antioxidant potential 
[7, 8]. In vitro cancer studies focused its antiapoptotic, anti-cell 
proliferative and anti-inflammatory efficacy using various cancer cell 
lines [9, 10]. However, there are no in vivo experimental studies to 
validate cromolyn efficacy on the expression pattern of inflammatory 
and angiogenic markers in DMBA induced oral carcinogenesis. The 
present study thus explores the anti-inflammatory and anti-angiogenic 
potential of cromolyn in 7, 12-dimethylbenz(a)anthracene induced 
hamster buccal pouch carcinogenesis. 
MATERIALS AND METHODS 
We purchased forty male golden Syrian hamsters from National Institute 
of Nutrition, Hyderabad, India. Animals were maintained in the 
Annamalai University Central Animal House, according to the ethical 
regulations issued by the Institutional Animal Ethics Committee 
(Register number 160/1999/CPCSEA). The animals were categorized 
into four groups, and the experimental protocol was followed as follows:  
Group I: Vehicle treated control hamsters [liquid paraffin alone 
three times a week for 14 w] 
Group II: DMBA alone treated hamsters [0.5% DMBA in liquid 
paraffin; three times a week, for 14 w] 
Group III: DMBA+cromolyn treated hamsters [Cromolyn 80 mg/kg 
bw [11]; three times a week for 14 w; alternate days of DMBA 
treatment] Group IV: Cromolyn alone treated hamsters [80 mg/kg 
bw; three times a week for 14 w] 
Cromolyn was administered along with a delivery agent (N-
cyclohexanoyl-L-leucine) in order to increase its bioavailability in 
the experimental animals [12]. The cervical dislocation procedure 
was followed to sacrifice the experimental animals at the end of the 
experimental period.  
Immunohistochemical analysis 
The polylysine coated tissue sections were treated with corresponding 
primary antibodies (NF-κB and COX-2) after usual routine procedure 
carried out for immunohistochemical analysis. The slides were 
incubated at 4 °C for overnight. The slides containing the immune 
complex were further treated with horseradish peroxidase-conjugated 
secondary antibodies and incubated for 2h at room temperature. The 
immune reaction was visualized under the light microscope, the slides 
by treating with the substrate of horseradish peroxidase, diamino 
benzidine. The slides were counterstained with hematoxylin when the 
acceptable color intensity was noticed [13]. 
Western blotting 
The proteins that are quantified in the tissue extracts of control and 
experimental animals are separated using SDS-PAGE electrophoresis 
and then transferred to PVDF membrane by electroblotting. The 
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membrane was probed with the primary antibodies (VEGF, iNOS, IL-6 
and IL-10), followed by incubation with the horseradish peroxidase-
conjugated secondary antibodies. The band formation was detected by 
treating with diamino benzidine and was then quantified densito-
metrically. β-actin served as an internal control [14]. 
Statistical analysis 
The densitometry analysis of molecular markers is expressed as 
mean±SD. The statistical significance between two groups was 
analyzed using One-way analysis of variance (ANOVA) followed by a 
Duncans multiple range test (DMRT). The two different groups were 
considered statistically significant if the p values were less than or 
equal to 0.05 between them. 
RESULTS 
The immune expression pattern of NF-κB and COX-2 in control and 
the experimental hamster is depicted in fig. 1. Over-expression of 
NF-κB and COX-2 was noticed in the buccal mucosa of hamsters 
treated with DMBA alone. Hamsters that received DMBA+cromolyn 
revealed expression pattern close to control hamsters. 
Western blotting analysis for the expression pattern of VEGF, iNOS, IL-6 
and IL-10 is shown in fig. 2 and fig. 3. We noticed an over-expression of 
VEGF, iNOS, IL-6 and IL-10 in hamsters treated with DMBA alone. Oral 
administration of cromolyn corrected the abnormalities in the above 
molecular markers expression pattern in DMBA treated hamsters. 
 
 
Fig. 1: Immuno expression pattern of NF-κB and COX-2 proteins observed in the buccal mucosa of control and experimental hamsters in 
each group, (A) NF-κB: A and D-Control and Cromolyn alone (an expression not detectable); B - DMBA alone (over expression); C-
DMBA+Cromolyn (down-regulated). (B) COX-2: E and H-Control and Cromolyn alone (expression not detectable), F-DMBA alone (over 
expression), G-DMBA+Cromolyn (down-regulated) 
 
 
Lane 1: Control, Lane 2: DMBA alone, Lane 3: DMBA+Cromolyn, 
Lane 4: Cromolyn alone 
Fig. 2: Expression pattern of VEGF, iNOS, IL-6, IL-10 in the buccal 
pouch tissues of control and experimental animals 
 
 
Fig. 3: Densitometric analysis of protein expression after 
normalization to β-actin in the buccal pouch tissues of control 
and experimental animals 
Values are represented as the mean±SD (n=10 male golden 
Syrian hamsters). Common superscripts between two groups-
not significant. Different superscripts between two groups- 
significant p<0.05 
DISCUSSION 
In the present study, hamsters that received the carcinogen alone 
(DMBA) developed oral tumors on their buccal pouches, and the 
incidence of the tumor was found to be 100%. Cromolyn 
administration to DMBA treated hamsters significantly suppressed 
the tumor formation, and the tumor incidence was 0%. However, we 
noticed mild dysplasia in the buccal pouches of hamsters treated 
with DMBA+cromolyn, which implies that cromolyn exhibited 
potent anticancer property by suppressing the tumor formation in 
DMBA, induced oral carcinogenesis.  
Chronic inflammation and angiogenesis are recognized as a hallmark 
characteristic of malignant neoplasm [15]. In the present study, we 
have analyzed the expression pattern of inflammatory and 
angiogenic markers in hamsters treated with DMBA and hamsters 
treated with DMBA+cromolyn. NF-κB serves as a signal 
transcription factor for the expression of several classes of proteins, 
including genes involved in the inflammatory response. The 
activated NF-κB enters into the nucleus and binds to COX-2 
promoters, thereby stimulating inflammatory response and 
carcinogenesis [16]. NF-κB plays a pivotal role in the transcriptional 
activation of angiogenesis factors, cytokines, anti-apoptotic proteins 
and cell adhesion molecules [17]. NF-κB plays a critical role in the 
genesis of various cancers, including oral cancer, if it is abnormally 
expressed [18]. NF-κB expression was found to be enhanced 
gradually from normal to precancerous lesions and to cancerous 
tissues [19]. Mounting and multiple studies showed over-expression 
of NF-κB in cancerous tissues [20]. While COX-2 exert its 
pathological effects in the early stages of carcinogenesis, NF-κB is 
involved in the late stages of carcinogenesis [21]. Sawhney et al. [22] 
reported that NF-κB over-expression occurred in the oral 
preneoplastic conditions and concluded that NF-κB over-expression 
was thus an early event in oral cancer. Wang et al. [23] found NF-κB 
activation as a major molecular mechanism in oral carcinogenesis. 
Our results corroborate these findings. 
COX-2 plays a pivotal role in the formation of prostaglandins from 
arachidonic acid. Abnormal activities or expression of COX-2 could 
result in immunosuppression, apoptotic failure, and increase in 
angiogenesis [24]. COX-2 inhibits the genes involved in the process of 
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apoptosis and promotes the genes of cell proliferation [25]. While 
there was no expression of COX-2 reported in normal tissues, higher 
expression was reported in hyperplastic and neoplastic tissues [26]. 
COX-2 expression was significantly increased in leukoplakia, epithelial 
dysplasia and in oral carcinoma [27]. Wang et al. [28] pointed out that 
over-expression of COX-2 may impact poor prognosis in patients with 
oral carcinoma. Mounting preclinical data highlighted the over-
expression of cyclooxygenase-2 in oral precancerous lesions and in 
malignant cancer [29, 30]. The present results confirm the previous 
findings. In the present study, cromolyn suppressed the over-
expression of NF-κB and COX-2 in hamsters treated with DMBA. The 
results thus suggest that cromolyn might have explored potent anti-
inflammatory efficacy during DMBA induced oral carcinogenesis. 
Chronic inflammation and dysregulation in various intracellular 
signaling cascades such as angiogenesis were also documented as 
responsible factors in several DMBA induced experimental 
carcinogenesis. iNOS, a proinflammatory gene, is regulated by NF-
κB, the major transcription factor, in eukaryotes. Inducible nitric 
oxide synthase (iNOS) mediates carcinogenesis via abundant 
generation of endogenous nitric oxide. Increase in endogenous nitric 
oxide (NO) could cause neoplastic transformation through extensive 
damage to DNA, inhibition of DNA repair and by negatively 
modulating p53 towards carcinogenesis [31, 32].  
The precise effect of nitric oxide (NO) on apoptosis, invasion, 
metastasis and angiogenesis has also been reported [33]. iNOS over-
expression was a common phenomenon in various cancers, 
including oral squamous cell carcinoma [34]. It has been pointed out 
that DMBA initiated skin carcinogenesis via over-expression of iNOS 
and COX-2 [35]. Over-expression if iNOS in the buccal mucosa of 
hamsters treated with DMBA alone. It has been suggested that 
agents that could be able to inhibit iNOS over-expression would 
emerge as a potent anticancer agent [36]. Cromolyn prevented the 
over expression of iNOS in the buccal mucosa of DMBA treated 
hamsters, which indicates its anti-inflammatory property during 
DMBA induced oral carcinogenesis. 
Neovascularization is the major characteristic feature of tumor cells 
and is an essential phenomenon to supply nutrients and oxygen to 
the growing tumors. VEGF, a major endothelial cell-specific growth 
factor, is involved in several important biological functions including 
vascular permeability, migration of cells and angiogenesis [37]. 
VEGF serves as a potent mitogen for vascular endothelial cells to 
initiate the process of angiogenesis. VEGF initiates angiogenic 
sprouting by binding with tyrosine kinase receptors present on the 
endothelial cells. Oral cancer progression has been associated with 
hypoxia-induced VEGF expression [38]. Over-expression of VEGF 
has been reported in several cancers using biochemical, immuno 
histochemical and molecular procedures [39]. Over-expression of 
VEGF was correlated with the poor prognosis of various cancers, 
including oral carcinoma [40]. The present findings are in line with 
the previous observation. Oral administration of cromolyn at a dose 
of 80 mg/kg bw suppressed the expression of VEGF in the buccal 
mucosa of hamsters treated with DMBA. The results of the present 
study thus suggest that cromolyn has the potential to inhibit the 
process of angiogenesis during DMBA induced oral carcinogenesis. 
Tumor cells develop a defense mechanism against the growth 
inhibitory potential of cytokines, which exist in the tumor 
microenvironment. IL-6 is a pleiotropic cytokine, which plays a crucial 
role in cell survival and proliferation, attenuation of the apoptotic 
signal and as a growth factor in various human tumors [41]. IL-6 
exhibit diverse biological effects, which are however cell and tissue 
dependent. IL-6 increased cell migration in various cancers including 
oral cancer [42]. It has also been reported that IL-6 facilitated 
metastasis in several cancers [43]. Higher expression of IL-6 transcript 
was shown in oral cancer patients with lymph node metastasis [44]. 
Serum IL-6 concentrations were found to be higher in oral cancer 
patients as compared to healthy subjects [45]. IL-10, an inhibitory 
immune cytokine, is secreted by various cell types including normal 
and carcinoma cells [46]. Wei Sung et al. [47] reported that IL-10 
produced by lung tumors stimulated tumor aggressiveness. It has also 
been pointed out that IL-10 has an immune regulating role in the lung 
tumor microenvironment [48]. IL-10 increased the abnormal 
proliferation of thyroid, melanoma and gastric cancer [49]. Previous 
studies pointed out the dual role of IL-10 in human cancer. While some 
studies claimed antitumor effect of IL-10 [50], a large number of in 
vivo experimental studies focused the tumor aggressive potential of IL-
10 [51]. The variation could be attributed to the biopsy taken from the 
tumor site since non-tumor immune cells also secrete IL-10. Cromolyn 
administration to DMBA treated hamsters significantly reduced the 
expression of IL-6 and IL-10, as evidenced by western blot analysis, in 
the buccal mucosa. Our results suggest that cromolyn might have 
inhibited the release of IL-6 and IL-10 to suppress the tumor 
formation in the buccal mucosa of DMBA treated hamsters. 
CONCLUSION 
Phytochemicals modulate intracellular signaling cascades towards 
inhibition, suppression or prevention of carcinogenesis. In the 
present study, cromolyn suppressed the formation of tumors in the 
buccal mucosa of hamsters by modulating the inflammatory and 
angiogenic markers towards inhibition of carcinogenesis. To 
conclude, cromolyn might have inhibited oral tumors formation 
through its anti-inflammatory and anti-angiogenic potential. Further 
studies are in progress to assess the cromolyn efficacy on other 
molecular pathways that are related to oral carcinogenesis. 
ACKNOWLEDGEMENT 
Financial assistance from University Grants Commission, New Delhi, 
in the form of UGC-BSR fellowship to Mr. S. Karthikeyan, is gratefully 
acknowledged. 
CONFLICT OF INTERESTS 
Declared None 
REFERENCES 
1. Coelho KR. Challenges of the oral cancer burden in India. J 
Cancer Epidemiol 2012:701-32. doi.org/10.1155/ 2012/ 
701932. [Article in Press] 
2. Sridharan G. Epidemiology, control and prevention of tobacco 
induced oral mucosal lesion in India. Indian J Cancer 2014;51:80-5. 
3. Manoharan S, Wani SA, Vasudevan K, Manimaran A, Prabhakar 
MM. Saffron reduction of 7,12-dimethylbenz[a]anthracene-
induced hamster buccal pouch carcinogenesis. Asian Pacific J 
Cancer Prevention 2013;14:951-7. 
4. Manoharan S, Panjamurthy K, Pugalendi P, Balakrishnan S, 
Rajalingam K, Vellaichamy L, et al. Protective role of 
Withaferin-A on red blood cell integrity during 7,12-
dimethylbenz[a]anthracene induced oral carcinogenesis. Afr J 
Tradit Complementary Altern Med 2008;6:94-102. 
5. Wei J, Xie G, Ge S, Qiu Y, Liu W, Lu A, et al. Metabolic 
transformation of DMBA-induced carcinogenesis and the 
inhibitory effect of salvianolic acid b and brovincamine 
treatment. J Proteome Res 2012;11:1302-16. 
6. Radley HG, Grounds MD. Cromolyn administration (to block 
mast cell degranulation) reduces necrosis of dystrophic muscle 
in mdx mice. Neurobiol Dis 2006;23:387-97. 
7. Motawi TM, Bustanji Y, EL-Maraghy SA, Taha MO, AlGhussein MAS. 
Naproxen and Cromolyn as new glycogen synthase kinase 3β 
Inhibitors for the amelioration of diabetes and obesity: An 
investigation by docking simulation and subsequent in vitro/in vivo 
biochemical evaluation. J Biochem Mol Toxicol 2013;27:425-36. 
8. Ionov ID. Inhibition of mast cell activity as a new approach to 
anticancer therapy. Int J Radiat Biol 1991;60:287-91. 
9. Motawi TM, Bustanji Y, El-Maraghy S, Taha MO, Al-Ghussein 
MA. Evaluation of naproxen and cromolyn activities against 
cancer cells viability, proliferation, apoptosis, P53
10. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on 
S100P interactions with RAGE and pancreatic cancer growth and 
invasion in mouse models. J Natl Cancer Inst 2006;98:1806-18. 
 and gene 
expression of survivin and caspase-3. J Enzyme Inhib Med 
Chem 2014;29:153-61. 
11. Beck PL, Morris GP, Wallace JL. Reduction of ethanol-induced 
gastric damage by sodium cromoglycate and FPL-52694. Role of 
beukotrienes, prostaglandins, and mast cells in the protective 
mechanism. Can J Physiol Pharmacol 1989;67:287-93.  
12. Leone-Bay A, Leipold H, Sarubbi D, Variano B, Rivera T, 
Baughman RA. Oral delivery of sodium cromolyn: preliminary 
studies in vivo and in-vitro. Br J Pharm Res 1996;13:222-6. 
Manoharan et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 321-324 
 
324 
13. Prabhakar MM, Vasudevan K, Karthikeyan S, Baskaran N, Silvan 
S, Manoharan S. Anti-cell proliferative efficacy of ferulic acid 
against 7,12-dimethylbenz(a)anthracene induced hamster buccal 
pouch carcinogenesis. Asian Pacific J Cancer Prevention 
2012;13:5207-11. 
14. Nalini N, Aranganathan S, Kabalimurthy J. Chemopreventive 
efficacy of hesperetin (citrus flavanone) against 1,2-
dimethylhydrazine-induced rat colon carcinogenesis. 
Toxicol Mech Methods 2012;22:397-408. 
15. Floor SL, Dumont JE, Maenhaut C, Raspe E. Hallmarks of cancer: 
of all cancer cells, all the time?. Trends Mol Med 2012;18:509-15. 
16. Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB 
(NF-kB) and cyclooxygenase-2 (COX-2) expression in the oral 
mucosa following cancer chemotherapy. Oral Oncol 
2007;43:395-401. 
17. Shen HM, Tergaonkar V. NF-kB signaling in carcinogenesis and 
as a potential molecular target for cancer therapy. Apoptosis 
2009;14:34-8. 
18. Johnson J, Shi Z, Liu Y, Stack MS. Inhibitors of NF-kappaB 
reverse cellular invasion and target gene upregulation in an 
experimental model of aggressive oral squamous cell 
carcinoma. Oral Oncol 2014;50:468-77. 
19. Bindhu OS, Ramadas K, Sebastian P, Pillai MR. High expression 
levels of nuclear factor kappa B and gelatinases in the 
tumorigenesis of oral squamous cell carcinoma. Head 
Neck Oncol 2006;28:916-25.  
20. Zhang Z, Ma J, Li N, Sun N, Wang C. Expression of nuclear 
factor-kappaB and its clinical significance in nonsmall-cell lung 
cancer. Annals Thoracic Surgery 2006;82:243-8. 
21. Pontes HA, Pontes FS, Fonseca FP, de Carvalho PL, Pereira EM, 
de Abreu MC, et al. Nuclear factor κB and cyclooxygenase-2 
immunoexpression in oral dysplasia and oral squamous cell 
carcinoma. Ann Diagn Pathol 2013;17:45-50. 
22. Sawhney M, Rohatgi N, Kaur J, Shishodia S, Sethi G, Gupta SD, et 
al. Expression of NF-kappaB parallels COX-2 expression in oral 
precancer and cancer: association with smokeless tobacco. Int J 
Cancer 2007;120:2545-56. 
23. Wang LJ, Zhou X, Wang W, Tang F, Qi CL, Yang X, et al. 
Andrographolide inhibits oral squamous cell carcinogenesis 
through NF-κB inactivation. J Dent Res 2011;90:1246-52.  
24. Nagatsuka H, Siar CH, Tsujigiwa H, Naomoto Y, Han PP, Gunduz 
M, et al. Heparanase and cyclooxygenase-2 gene and protein 
expressions during the progression of oral epithelial dysplasia 
to carcinoma. Ann Diagn Pathol 2012;16:354-61. 
25. Qian Y, Shao YS, Cao ZY. The role of COX-2 in tongue squamous cell 
carcinoma Tca8113 cell proliferation. Oral Med Res 2012;28:395-7. 
26. Zhao M, Liu Y, Fu XL. The expression of COX-2 in oral 
papilloma, oral lichen planus and oral squamous cell 
carcinoma. Oral Med Res 2013;29:142-4.  
27. Amirchaghmaghi M, Mohtasham N, Mozaffari PM. Comparison 
of COX2 expression between oral squamous cell carcinoma, 
leukoplakia and normal mucosa. J Contemporary Dental 
Practice 2012;13:205-9. 
28. Wang ZM, Liu J, Liu HB, Ye M, Zhang YF, Yang DS. Abnormal COX2 
protein expression may be correlated with poor prognosis in oral 
cancer: a meta-analysis. BioMed Res Int 2014;2014:364-7. 
29. Seyedmajidi M, Shafaee S, Siadati S, Khorasani M, Bijani A, 
Ghasemi N. Cyclo-oxygenase-2 expression in oral squamous 
cell carcinoma. J Cancer Res Ther 2014;10:1024-9. 
30. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, 
DuBois RN. Cyclooxygenase-2 and epidermal growth factor 
receptor: pharmacologic targets for chemoprevention. J Clin 
Oncol 2005;23:254-66.  
31. Youn J, Lee JS, Na HK, Kundu JK, Surh YJ. Resveratrol and 
piceatannol inhibit iNOS expression and NF-kappaB activation 
in dextran sulfate sodium-induced mouse colitis. Nutr Cancer 
2009;61:847-54. 
32. Yang L, Wang Y, Guo L, Wang L, Chen W, Shi B. The expression 
and correlation of iNOS and p53 in oral squamous cell 
carcinoma. BioMed Res Int 2015;12. doi.org/ 10.1155/ 
2015/637853. [Article in Press] 
33. Crowell JA, Steele VE, Sigman CC, Fay JR. Is inducible nitric 
oxide synthase a target for chemoprevention? Mol Cancer Ther 
2003;2:815-23. 
34. Brennan PA, Dennis S, Poller D, Quintero M, Puxeddu R, Thomas GJ. 
Inducible nitric oxide synthase: correlation with extracapsular 
spread and enhancement of tumor cell invasion in head and neck 
squamous cell carcinoma. Head Neck Oncol 2008;30:208-14. 
35. Tsai ML, Lai CS, Chang YH, Chen WJ, Ho CT, Pan MH. 
Pterostilbene, a natural analogue of resveratrol, potently 
inhibits 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-
tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin 
carcinogenesis. Food Funct 2012;3:1185-94.  
36. Hao L, Zhang C, Qiu Y, Wang L, Luo Y, Jin M, et al. Recombination of 
CXCR4, VEGF, and MMP-9 predicting lymph node metastasis in 
human breast cancer. Cancer Lett 2007;253:34-42. 
37. Tsai RL, Ho BY, Pan TM. Red mold rice mitigates oral 
carcinogenesis in 7,12-dimethyl-1,2-benz[a]anthracene-
induced oral carcinogenesis in the hamster. J Evidence-Based 
Complementary Altern Med 2011:245-309. doi: 10.1093/ 
ecam/nep215. [Epub 2011 May 4] 
38. Kishimoto K, Yoshida S, Ibaragi S, Yoshioka N, Okui T, Hu GF, et al. 
Hypoxia-induced up-regulation of angiogenin, besides VEGF, is 
related to the progression of oral cancer. Oral Oncol 
2012;48:1120-7. 
39. Aggarwal S, Devaraja K, Sharma SC, Das SN. Expression of 
vascular endothelial growth factor (VEGF) in patients with oral 
squamous cell carcinoma and its clinical significance. Clin Chim 
Acta 2014;436:35-40. 
40. Shang ZJ, Li JR, Li ZB. Upregulation of serum and tissue vascular 
endothelial growth factor correlates with angiogenesis and 
prognosis of oral squamous cell carcinoma. J Oral Maxillofac 
Surg 2007;65:17-21. 
41. Lin HY, Hou SC, Chen SC, Kao MC, Yu CC, Funayama S, et al. (-)-
Epigallocatechin gallate induces Fas/CD95-mediated apoptosis 
through inhibiting constitutive and IL-6-induced JAK/STAT3 
signaling in head and neck squamous cell carcinoma cells. J 
Agric Food Chem 2012;60:2480-9. 
42. Chuang JY, Huang YL, Yen WL, Chiang IP, Tsai MH, Tang CH. 
Syk/JNK/AP-1 signaling pathway mediates interleukin-6-
promoted cell migration in oral squamous cell carcinoma. Int J 
Mol Sci 2014;15:545-59. 
43. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-
6 trans-signaling information and progression of malignant 
ascites in ovarian cancer. Cancer Res 2011;71:424-34. 
44. Nagata M, Fujita H, Ida H, Hoshina H, Inoue T, Seki Y, et al. 
Identification of potential biomarkers of lymph node 
metastasis in oral squamous cell carcinoma by cDNA 
microarray analysis. Int J Cancer 2003;106:683-9. 
45. John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, et al. 
Interleukin 6 and interleukin 8 as potential biomarkers for oral 
cavity and oropharyngeal squamous cell carcinoma. Arch 
Otolaryngol Head Neck Surg 2004;130:929-35. 
46. Chuang CY, Sung WW, Wang L, Lin WL, Yeh KT, Su MC, et al. 
Differential impact of IL-10 expression on survival and relapse 
between HPV16-positive and negative oral squamous cell 
carcinomas. PLoS One 2012;7:e47541. 
47. Sung WW, Wang YC, Lin PL, Cheng YW, Chen CY, Wu TC, et al. 
IL-10 promotes tumor aggressiveness via upregulation of 
CIP2A transcription in lung adenocarcinoma. Clin Cancer Res 
2013;19:4092-103. 
48. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the 
immune response against cancer: a counterpoint. 
J Leukocyte Biol 2005;78:1043–51. 
49. Todaro M, Zerilli M, Ricci-Vitiani L, Bini M, Perez Alea M, Maria 
Florena A, et al. Autocrine production of interleukin-4 and 
interleukin-10 is required for survival and growth of thyroid 
cancer cells. Cancer Res 2006;66:1491–9. 
50. Huang S, Xie K, Bucana CD, Ullrich SE, Bar-Eli M. Interleukin 10 
suppresses tumor growth and metastasis of human melanoma 
cells: potential inhibition of angiogenesis. Clin Cancer Res 
1996;2:1969-79. 
51. Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Nunez G, et al. 
Interleukin-10 ablation promotes tumor development, growth, 
and metastasis. Cancer Res 2012;72:420-9. 
 
